Sunday, October 21, 2018
- 9:00AM-11:00AM
-
Abstract Number: 490
Catastrophizing in Rheumatoid Arthritis
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 62
CCR6+CD4+ T Cells Drive IL-23R Signaling-Dependent Progression of Antigen-Induced Arthritis
Rheumatoid Arthritis – Animal Models Poster- 9:00AM-11:00AM
-
Abstract Number: 30
CD21lo Cells Are Increased in Patients with Systemic Sclerosis and May be Associated with Interstitial Lung Disease
B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 29
CD70-Mediated CD27 Downregulation Contributed to Regulatory B10 Cell Impairment in Rheumatoid Arthritis
B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 779
Cerebrospinal Fluid Biomarkers for Diagnosing Neuropsychiatric SLE: A Systematic Review and Meta-Analysis
Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity- 9:00AM-11:00AM
-
Abstract Number: 284
Challenges and Barriers to Employment That Persons with Osteoarthritis Face at Work Due to Their Condition
Health Services Research Poster I – ACR/ARHP- 9:00AM-11:00AM
-
Abstract Number: 568
Change in RF and Anti-CCP Isotype Levels in RA Patients Treated with Anti-TNF, Abatacept, Rituximab or Tocilizumab and Correlation with Clinical and Radiographic Outcomes: Data from a Randomized Trial
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology- 9:00AM-11:00AM
-
Abstract Number: 210
Changes in Alcohol Use in Patients with Rheumatoid Arthritis: Associations with Disease Activity, Health Status, and Mortality
Epidemiology and Public Health Poster I: Rheumatoid Arthritis- 9:00AM-11:00AM
-
Abstract Number: 584
Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology- 9:00AM-11:00AM
-
Abstract Number: 579
Changes in DNA Methylation Identify Response to Treatment with Methotrexate and TNF Inhibitors Among RA Patients
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology- 9:00AM-11:00AM
-
Abstract Number: 685
Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment- 9:00AM-11:00AM
-
Abstract Number: 553
Channeling to Treatment and Associated Changes in Disease Activity Over 12 Months in Patients With RA Treated With Abatacept Versus Other DMARDs in Real-World Community Practice Settings
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology- 9:00AM-11:00AM
-
Abstract Number: 495
Characteristics of Metabolic Syndrome in Men and Women with Early Rheumatoid Arthritis
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 597
Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry